title: CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
abstract: Anaplastic large cell lymphoma (ALCL) represents a generally recognized group of large cell lymphomas. Defining features consist of a proliferation of predominantly large lymphoid cells with strong expression of the cytokine receptor CD30 and a characteristic growth pattern. With the use of molecular and clinical criteria, 3 entities of ALCL have been identified: primary systemic anaplastic lymphoma kinase (ALK)(+) ALCL, primary systemic ALK(-) ALCL, and primary cutaneous ALCL. ALK expression is caused by chromosomal translocations, most commonly t(2;5). ALK(+) ALCL predominantly affects young male patients and, if treated with chemotherapy, has a favorable prognosis. It shows a broad morphologic spectrum, with the "common type," the small cell variant, and the lymphohistiocytic variant being most commonly observed. The knowledge of the existence of these variants is essential in establishing a correct diagnosis. ALK(-) ALCL occurs in older patients, affecting both genders equally and having an unfavorable prognosis. The morphology and the immunophenotype of primary cutaneous ALCL show an overlap with that of lymphomatoid papulosis. Both diseases have an excellent prognosis, and secondary systemic dissemination is only rarely observed. The described ALCL entities usually derive from cytotoxic T cells. In contrast, large B-cell lymphomas with anaplastic morphology are believed to represent not a separate entity but a morphologic variant of diffuse large B-cell lymphoma. Malignant lymphomas with morphologic features of both Hodgkin disease and ALCL have formerly been classified as Hodgkin-like ALCL. Recent immunohistologic studies, however, suggest that ALCLs Hodgkin-like represent either cases of tumor cell-rich classic Hodgkin disease or (less commonly) ALK(+) ALCL or ALK(-) ALCL. (Blood. 2000;96:3681-3695)
authors.affiliation: Institute of Pathology, University Hospital Benjamin Franklin, Free University, Berlin, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Stein
authors.forename: H D
authors.initials: HD
authors.lastname: Foss
authors.forename: H
authors.initials: H
authors.lastname: Dürkop
authors.forename: T
authors.initials: T
authors.lastname: Marafioti
authors.forename: G
authors.initials: G
authors.lastname: Delsol
authors.forename: K
authors.initials: K
authors.lastname: Pulford
authors.forename: S
authors.initials: S
authors.lastname: Pileri
authors.forename: B
authors.initials: B
authors.lastname: Falini
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D015321:Gene Rearrangement; D006689:Hodgkin Disease; D006801:Humans; D016130:Immunophenotyping; D017728:Lymphoma, Large-Cell, Anaplastic / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D009687:Nuclear Proteins / Q000235:genetics; D000090243:Nucleophosmin; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases; D014178:Translocation, Genetic
chemical_list: D009687:Nuclear Proteins; D000090243:Nucleophosmin; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases